Acute myeloid leukemia (AML) with CEBPA mutations is determined as provisional entity in the current WHO. A difference in clinical outcome between single- (sm) and double-mutated (dm) cases has been reported, whereupon dm cases were shown to be associated with longer overall survival (OS). The occur...
This model examines the role of helper and cytotoxic T cells in an anti-tumour response, with implicit inclusions of immunosuppressive effects. The model demonstrates the dependence of immunoediting on infilftration by helper and cytotoxic T cells, as well as the importance of these cells in mediati...
The clinical impact of aberrant CEBPA promoter methylation (PM) in AML is controversial discussed. The aim of this study was to clarify the significance of aberrant CEBPA PM with regard to clinical features in a cohort of 572 de novo AML with wildtype CEBPA and normal karyotype. The distal promoter ...
